title: [Combined endobronchial and percutaneous radiotherapy after implanting the nitinol alloy endotrachial stent for advanced lung carcinoma].
abstract: OBJECTIVE
  For the purpose to observe the effectiveness of treatment in late stage patients with bronchogenic carcinoma by implanting nitinol alloy endotrachial stent, combined with endobronchial 192 iridium (Ir) and percutaneous radiotherapy.
  
  
  METHODS
  The nitiol alloy endotrachial stent was put into the site of airway stenosis through a special introducer under direct optical fibrobronchoscopy without the help of X-ray examination nor guided steel-line. 192 Ir was inserted to the site of tumor via bronchofiberscope for endobronchial irradiation combining with percutaneous radiotherapy alternately.
  
  
  RESULTS
  In all 20 patients, 7 cases (35%) were completely cured and 11 cases (55%) showed partial recovery. The other 2 cases, no change or deteriorated. The 90% effective rate was significantly higher than 60% of control group (P < 0.05).
  
  
  CONCLUSIONS
  Dyspnea of patients could be immediately relieved after endobronchial stent was inserted. Combined endobronchial and percutaneous radiotherapy obviously alleviated the obstruction caused by trachial or bronchial neoplasms. The results suggested the combined therapy led to much better objective therapeutic effect and symptomatic relief than single percutaneous radiotherapy.
authors.affiliation: Bethune International Peace Hospital, Shijiazhuang 050082.
authors.forename: G
authors.initials: G
authors.lastname: Yang
authors.forename: M
authors.initials: M
authors.lastname: Gao
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000368:Aged; D000497:Alloys; D000971:Antineoplastic Combined Chemotherapy Protocols; D001918:Brachytherapy / Q000379:methods*; D001980:Bronchi; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone; D011344:Procarbazine; D015607:Stents; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D000497:Alloys; D007496:Iridium Radioisotopes; C013616:nitinol; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone